Altimmune, Inc. (NASDAQ:ALT) Holdings Boosted by Barclays PLC

Barclays PLC raised its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 93.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 155,741 shares of the company’s stock after purchasing an additional 75,064 shares during the quarter. Barclays PLC’s holdings in Altimmune were worth $956,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Bellevue Group AG grew its stake in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Stifel Financial Corp grew its position in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Altimmune by 318.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock worth $259,000 after buying an additional 32,072 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ALT shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group initiated coverage on Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.71.

Altimmune Stock Down 8.1 %

Shares of ALT stock opened at $6.23 on Wednesday. Altimmune, Inc. has a 12 month low of $5.28 and a 12 month high of $14.84. The company has a market cap of $443.11 million, a PE ratio of -4.02 and a beta of 0.22. The business’s 50 day moving average is $8.08 and its two-hundred day moving average is $7.20.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter. During the same quarter last year, the business earned ($0.39) EPS. As a group, equities analysts expect that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.